Drugs / PF-07260437
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05067972 | Oct 2021 → Oct 2023 | breast neoplasm, endometrium neoplasm, ovarian neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07260437 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05067972 ↗ |
| Modality | Monoclonal antibody | “B7-H4 x CD3 bi-specific mAb” NCT05067972 ↗ |
| Route | Subcutaneous | “received escalating doses of PF-07260437 (with/without priming dose) subcutaneously every two weeks” PMID 42171881 ↗ May 2026 |